Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

Here's Why You Should Retain PRA Health (PRAH) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

by Zacks Equity Research

Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark

by Zacks Equity Research

Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.

BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch

by Zacks Equity Research

BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.

NextGen (NXGN) Announces Positive Telehealth Survey Results

by Zacks Equity Research

NextGen's (NXGN) recent survey indicates growing preference for telehealth services.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.

Allscripts (MDRX), Lash Group Team Up for Better Patient Care

by Zacks Equity Research

Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.

Trina Mukherjee headshot

3 Stocks to Bank on Rebounding Outpatient Home Health Industry

by Trina Mukherjee

Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well-poised to gain from the prospects.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

by Zacks Equity Research

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

by Zacks Equity Research

Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.

Veeva Systems' (VEEV) Cloud Offerings Aid Drug Development

by Zacks Equity Research

Veeva Systems' (VEEV) Cloud applications help in simplifying and accelerating drug development on an industry-wide basis.

Ecolab (ECL) Launches Roach Control Device for Food Outlets

by Zacks Equity Research

Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

LHC Group (LHCG) Forays Into Tucson Market With New Buyout

by Zacks Equity Research

LHC Group (LHCG) agrees to buy two Casa de la Luz provider locations to expand its hospice service in the Tucson market.

    Here's Why You Should Invest in Integer Holdings (ITGR) Stock

    by Zacks Equity Research

    Integer Holdings (ITGR) continues to gain traction from portfolio management.

    NextGen (NXGN) Implements API to Aid COVID-19 Vaccination

    by Zacks Equity Research

    NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.

    DVA vs. AMED: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    DVA vs. AMED: Which Stock Is the Better Value Option?

    PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout

    by Zacks Equity Research

    PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.

    Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome

    by Zacks Equity Research

    Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.